NasdaqGM:VCYTBiotechs
Can Veracyte (VCYT) Stay Reasonable After A 145% Rally?
Veracyte’s share price has climbed sharply over the past year, yet the valuation checks are pulling in different directions. An intrinsic value estimate based on a Discounted Cash Flow (DCF) suggests the stock trades below that estimate, while market multiples lean expensive and the broader score is weak.
Veracyte has returned 144.5% over the past year, which puts extra focus on whether recent gains already reflect the company’s prospects.
Rising earnings estimates and growth plans in areas...